Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

29.51USD
23 Feb 2018
Change (% chg)

$0.41 (+1.41%)
Prev Close
$29.10
Open
$29.37
Day's High
$29.51
Day's Low
$28.46
Volume
527,133
Avg. Vol
870,319
52-wk High
$32.49
52-wk Low
$18.04

Latest Key Developments (Source: Significant Developments)

Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Tuesday, 13 Feb 2018 04:05pm EST 

Feb 13 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA.EXELIXIS INC - ‍EXELIXIS PLANS TO INITIATE A PIVOTAL PHASE 3 TRIAL LATER THIS YEAR​.EXELIXIS INC - ‍54 PERCENT OBJECTIVE RESPONSE RATE AND 43 PERCENT STABLE DISEASE OBSERVED AMONG 35 EVALUABLE PATIENTS​.  Full Article

Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS.EXELIXIS INC- AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NOVEL ONCOLOGY COMPOUNDS TARGETING CASEIN KINASE 1 ALPHA.EXELIXIS INC- WILL PAY STEMSYNERGY UPFRONT PAYMENT OF $3 MILLION AND UP TO $3.5 MILLION IN INITIAL RESEARCH AND DEVELOPMENT FUNDING.EXELIXIS INC- CO WILL BE SOLELY RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS THAT ARISE FROM COLLABORATION.  Full Article

Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab
Thursday, 4 Jan 2018 08:00am EST 

Jan 4 (Reuters) - Exelixis Inc ::EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB.EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC.  Full Article

FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC
Tuesday, 19 Dec 2017 03:44pm EST 

Dec 19 (Reuters) - FDA::FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC.FDA SAYS GRANTED EXELIXIS' CURRENTLY APPROVED TREATMENT OPTION BROADENED LABEL THAT NOW INCLUDES ALL ELIGIBLE PATIENTS WITH ADVANCED RCC.  Full Article

Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma
Tuesday, 19 Dec 2017 02:54pm EST 

Dec 19 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - APPROVAL OF CABOMETYX TABLETS EXPANDS INDICATION AND COMES WELL IN ADVANCE OF PDUFA DATE OF FEBRUARY 15, 2018.  Full Article

Exelixis reports Q3 earnings per share $0.26
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Exelixis Inc :Exelixis announces third quarter 2017 financial results and provides corporate update.Q3 earnings per share $0.26.Q3 revenue $152.5 million versus $62.2 million.Q3 revenue view $104.9 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.08 -- Thomson Reuters I/B/E/S.Exelixis Inc - ‍is updating its guidance that total costs and operating expenses for full year will be between $285 million and $295 million​.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 06:58am EDT 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

Exelixis Q2 earnings per share $0.06
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Exelixis Inc :Exelixis announces second quarter 2017 financial results and provides corporate update.Q2 revenue $99 million versus I/B/E/S view $85.3 million.Q2 earnings per share $0.06.Q2 earnings per share view $0.04 -- Thomson Reuters I/B/E/S.Exelixis Inc says company is reiterating its previously provided guidance that total costs and operating expenses for full year.  Full Article

Exelixis announces settlement of dispute with Genentech
Thursday, 20 Jul 2017 07:00am EDT 

July 20 (Reuters) - Exelixis Inc :Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib.Exelixis Inc - ‍Companies define new revenue and cost-sharing terms for all commercial applications of Cobimetinib​.Exelixis Inc - ‍Cobimetinib's clinical development program includes three ongoing or planned phase 3 pivotal trials​.Exelixis Inc - ‍Settlement of dispute with Genentech, member of Roche Group, on collaboration for development,commercialization of Cobimetinib.Exelixis Inc - ‍Exelixis remains eligible for royalties on Cotellic sales according to terms of original 2006 agreement​.  Full Article

Exelixis Q1 earnings per share $0.05
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Exelixis Inc ::Exelixis announces first quarter 2017 financial results and provides corporate update.Q1 earnings per share $0.05.Q1 revenue $80.9 million versus I/B/E/S view $65.2 million.Q1 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S.Exelixis -reiterating previously provided guidance that total costs and operating expenses for full year will be between $290 million and $310 million for 2017.  Full Article

BRIEF-Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA